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Ever since the Asymptomatic Carotid Atherosclerosis Study
(ACAS) Study1 reported that an increased perioperative stroke rate
following carotid endarterectomy (CEA) in female patients greatly
diminished or possibly eliminated the potential benefit of prophy-
lactic CEA, there has been controversy and concern regarding the
outcome of cerebrovascular interventions in female patients. In a
subsequent large single-institutional study addressing this specific
issue, men and women were found to have equal rates of periop-
erative myocardial infarction (MI), mortality and stroke following
CEA.2 However, the cohort of patients with the highest perioper-
ative stroke rate was symptomatic female patients, with a stroke
incidence of 3.0% following CEA.2 Clearly, symptomatic women
may represent a cohort of patients with increased risk.
The majority of the studies on this topic have compared the
outcome of female patients to male patients. While these are worth-
while comparisons, one needs to keep in mind that it remains unclear
whether the natural history and outcome of patients with severe
cerebrovascular disease differs based on sex. It is certainly feasible that
women with symptomatic severe carotid artery stenosis may have a
worse outcome than corresponding male patients when treated with
“bestmedical” or noninterventional therapies. It is possible, of course,
that symptomatic female patients would be at a higher risk of future
stroke compared with men if no intervention were performed, and
would still benefit from cerebrovascular intervention as opposed to
medical management. Hence, the truly important comparison is not
female outcome vsmale outcome, but rather female outcome based on
the treatment performed: what is the best treatment for symptomatic
female patients with severe carotid artery disease? Should symptom-
atic female patients be treated with CEA, or with carotid artery
angioplasty and stenting (CAS)?
With these issues in mind, Drs. Paraskevas, Mikhailidis, and
Veith have authored a provocative letter stating that “CAS is not an
acceptable ‘alternative’ to CEA in this group of patients.” Their
concern stems from the recent AHA/ASA Guidelines,3 which do
clearly recommendCAS as an “alternative to CEA for symptomatic
patients.” Dr. Paraskevas and his coauthors cite subsequent litera-
ture from the Carotid Revascularization Endarterectomy Versus
Stenting (CREST) trial,4 as well as a recently published review of
the Nationwide Inpatient Sample (NIS)5 to support their conclu-
sion regarding the inferior outcome of CAS in symptomatic
women. As seen in the Table below, the CREST trial reports a
periprocedural stroke rate in symptomatic women of 7.5% for CAS
vs 2.7% with CEA (P  .03).4 The long-term rate of stroke in
symptomatic women from the CREST report is 10.4% with CAS,
vs 6.9% with CEA (P .18).4 Finally, the review of the NIS reports
a periprocedural stroke rate in symptomatic women of 6.2% with
CAS vs 3.4% for CEA (P  .1).5
In summary, data from both a large randomized prospective
trial and an extensive national database clearly suggest a poorer
outcome following CAS in symptomatic female patients. Based on
the existing literature, as delineated above, I share the authors’
concern regarding the appropriateness of CAS in symptomatic
female patients. Of course, an individual treatment decision with
regard to a particular patient must take into account many specific
details, including both anatomic factors and patient comorbidities.
However, the existing literature appears to show that CEA may be
the preferred treatment in female patients who warrant interven-
tion for symptomatic cerebrovascular disease, unless compelling
reasons exist to perform CAS.
a
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egarding “Repairing immediate proximal endoleaks
uring abdominal aortic aneurysm repair”
Rajani et al1 retrospectively reviewed data of 72 infrarenal
bdominal aortic aneurysm (AAA) patients with an intraoperatively
iagnosed type Ia endoleak requiring a Palmaz stent or covered
tent graft cuff placement. They concluded that both methods
ppear to be durable long-term options to facilitate endovascular
xclusion of AAA, with the results that no recurrent type Ia
ndoleak developed in the Palmaz stent group and three reinter-
entions were required in the cuff group. Given the lack of data
able. Representative periprocedural stroke rates
eported in the literature in symptomatic women
ndergoing carotid endarterectomy and carotid artery
ngioplasty and stenting
troke rate in
ymptomatic women CEA CAS P value
REST, perioperative4 2.7% 7.5% 0.03
REST, long-term4 6.9% 10.4% 0.2
IS5 3.4% 6.2% 0.1
REST, Carotid Revascularization Endarterectomy Versus Stenting; NIS,
ationwide Inpatient Sample.ssessing long-term outcomes of cuff and Palmaz (Cordis, Miami
akes, Fla) stent placement after immediate type Ia endoleak, we
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conclusions.
Qu et al2 reported 114 infrarenal AAA patients with short or
highly angulated necks who underwent endovascular aortic repair
(EVAR) using the Powerlink endograft (Endologix, Irvine, Calif),
with proximal aortic extension and with or without use of a Palmaz
stent; of these, 83 (72.8%) received a proximal Palmaz stent.
Aneurysmal exclusion was successful in 108 patients, with 6 exhib-
itingminor type Ia endoleak that remained under observation. The
2.6-year follow-up showed four (3.4%) continued type Ia en-
doleaks, which were revised with a proximal aortic extension or
Palmaz stent, or both.
We updated our experience more recently with data through
October 2009 involving 189 AAA patients with challenging “off-
label” neck anatomy in our center. These patients underwent
EVAR with the Powerlink endografts, implanted anatomically
from the aortoiliac bifurcation to the renal artery level with a
proximal aortic extension and with or without Palmaz stent, and of
these, 134 (70.9%) received the proximal Palmaz stent. Nine
patients (4.8%) with minor primary type I endoleaks were left
under observation. The average 3.2-year follow-up results showed
six (3.2%) continuing primary type Ia endoleaks, which were all
revised with aortic extension or Palmaz stent, or both. A reduction
in mean aneurysm sac diameters and volumes has been noted at
every follow-up interval.
In summary, proximal stent graft cuff and Palmaz stent place-
ment appear to be durable long-term options to facilitate EVAR in
infrarenal AAA patients with intraoperative type Ia endoleaks or
short/angulated necks. Our results also suggested that building up
the endovascular exclusion system in the AAA patients with intra-
operative proximal type I endoleaks or hostile necks using the
Powerlink main device maybe more durable to prevent distal
migration and postoperative type Ia endoleak.
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We appreciate the comments of Drs Raithel, Wu, and Qu.
hey are to be congratulated on their experience in treating
neurysms with complicated proximal necks, or “off-label” neck
natomy. The rates of type Ia endoleak development in their series
ppear to be similar to the data we provided in ours, as are the
utcomes of treatment. Our study did include the use of a variety
f stent grafts, but we were not able to provide adequate statistical
valuation of whether one type of graft performed better in this
ituation compared with others. Outcomes appeared equivalent
egardless of the stent graft used, but the study did not have
ufficient power to address this more fully.
It is becoming more apparent that the use of stent grafts to
reat aneurysms with anatomy that fall outside of the “indications
or use” may not be associated with acceptable long-term out-
omes.1 Although the use of adjuncts, such as aortic cuffs and
alloon-expandable stents, allow an endovascular approach to
vercome the obstacle of an unfavorable neck, future advance-
ents in endografting technology will provide a better alternative.
ith the development of fenestrated endografts, in particular,
ff-the-shelf models, proximal (and distal) landing zones will be
asily extended to a healthier segment of aorta in which to obtain
seal. We anticipate this will improve our long-term outcomes and
rovide a better alternative when the proximal landing zone is less
han ideal.
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